What Causes High Myelocytes in a Blood Count?

Myelocytes appear in a blood count when the bone marrow releases white blood cells before they are fully mature, a phenomenon most often triggered by severe infection, bone marrow disease, or intense physiological stress. In a healthy person, myelocytes stay inside the marrow while they finish developing, so finding them circulating in the blood is a signal that something has disrupted the normal production or release process. The list of possible causes ranges from treatable bacterial infections to blood cancers and marrow-invading tumors, and the clinical meaning depends heavily on the context in which they show up.

Why Myelocytes Do Not Normally Appear in Blood

White blood cells, particularly the type called neutrophils, develop through a series of stages inside the bone marrow. A stem cell gives rise to progressively more specialized precursor cells, passing through stages that include the myeloblast, promyelocyte, myelocyte, metamyelocyte, band cell, and finally the mature segmented neutrophil. Under normal conditions, only the last two stages (bands and mature neutrophils) are released into the bloodstream. Myelocytes are several steps too early in that sequence to be circulating.

Neutrophils are the most abundant white blood cell, and their production in the bone marrow follows a continuous process of differentiation from stem cells through multiple intermediate stages before mature cells enter the circulation.¹ The marrow acts as a gatekeeper, holding back immature cells until they are equipped with the full complement of enzymes, receptors, and structural features needed to fight pathogens. When myelocytes do escape into the bloodstream, it means either the marrow is being pushed so hard it cannot wait for cells to finish maturing, or the marrow’s normal architecture has been disrupted in a way that lets immature cells leak out.

Severe Infections and the “Left Shift”

The single most common reason for myelocytes to appear in a blood count is a serious bacterial infection. When the body detects a large-scale infection, the bone marrow ramps up neutrophil production dramatically. If demand outpaces the supply of fully mature cells, the marrow starts releasing younger cells, including myelocytes and metamyelocytes, into the circulation. Doctors call this a “left shift,” a term that dates back to the era when lab reports listed cell maturity from left (immature) to right (mature).

In sepsis, the shift can be extreme. One study monitoring blood levels of immature neutrophils in patients with systemic inflammation found that patients who died within one week had much higher levels of myelocytes and metamyelocytes (a median of about 9%) compared to patients who died later (median around 0.5%). Myelocyte and metamyelocyte levels were higher in patients with confirmed sepsis than in healthy controls, where these cells are essentially absent.² A severe left shift with immature precursors flooding the blood can occasionally produce white blood cell counts so high that the picture mimics leukemia, a phenomenon called a leukemoid reaction. In these cases, the bone marrow itself is structurally intact and there is no cancerous cell growth; the marrow is simply responding aggressively to the infection.³

Leukemoid reactions are not limited to adults. Newborns in particular can mount enormous white cell responses to sepsis. A case report described a preterm, extremely low-birth-weight infant who developed a leukemoid reaction during early-onset sepsis caused by a drug-resistant bacterial infection.⁴ In neonates, distinguishing a reactive flood of immature cells from an actual blood cancer requires careful clinical judgment, because the blood picture can look alarmingly abnormal even when the underlying cause is infectious.

Bone Marrow Disorders and Blood Cancers

When myelocytes show up in the blood without an obvious infection or other acute stress, the concern shifts toward diseases of the bone marrow itself. Chronic myeloid leukemia (CML) is the classic example. In CML, a genetic mutation drives uncontrolled production of myeloid cells at every stage of maturity, flooding the blood with myelocytes, metamyelocytes, and other precursors alongside mature white cells. The presence of myelocytes in a routine blood count is sometimes the first clue that prompts a CML workup.

Myeloproliferative neoplasms other than CML can also push immature cells into the bloodstream. In myelofibrosis, scar tissue gradually replaces healthy marrow, squeezing out the normal production space. The remaining marrow compensates by pushing cells out before they are ready, producing what pathologists call a leukoerythroblastic blood picture, where both immature white cells (including myelocytes) and immature red cells (nucleated red blood cells) appear together.⁵ Acute myeloid leukemia can similarly cause circulating myelocytes, though in AML the cells tend to be even more immature (blasts), and the clinical picture usually looks more dramatic and moves faster than in chronic diseases.

When Solid Tumors Invade the Marrow

Blood cancers are not the only malignancies that disrupt the marrow. Cancers originating elsewhere in the body, particularly those from the prostate, breast, lung, and stomach, can metastasize to the bone marrow. When tumor cells physically colonize the marrow space, they crowd out normal blood-producing tissue and damage the barrier that ordinarily keeps immature cells from entering the bloodstream. The result is a leukoerythroblastic reaction similar to what happens in myelofibrosis: myelocytes, metamyelocytes, and nucleated red blood cells appear in the peripheral blood.

A study of patients with non-blood cancers whose tumors had spread to the bone marrow found that a leukoerythroblastic reaction was present in roughly a third of cases.⁶ In advanced prostate cancer, for instance, bone marrow examination after a leukoerythroblastic blood picture revealed diffuse infiltration of the marrow by prostate cancer cells.⁷ For some patients, the appearance of immature cells on a routine blood count is the first indication that a known cancer has spread to the bones, making the finding clinically significant even before imaging confirms the metastasis.

Medications and Recovery from Chemotherapy

Certain medical treatments can trigger the release of myelocytes as a predictable side effect. Growth factors like G-CSF (granulocyte colony-stimulating factor) and GM-CSF (granulocyte-macrophage colony-stimulating factor) are commonly given to patients recovering from chemotherapy to speed up the return of their white blood cells. These drugs work by stimulating the bone marrow to produce neutrophils faster, but the tradeoff is that some immature cells get pushed into circulation before they are fully developed.

Research on patients receiving high-dose chemotherapy followed by bone marrow transplant showed that G-CSF and GM-CSF both accelerated the recovery of myeloid cells. G-CSF in particular caused earlier neutrophil recovery in the bloodstream, while GM-CSF stimulated production at a deeper level within the marrow.⁸ During this recovery phase, blood counts often show myelocytes and other immature forms, and this is generally considered a reassuring sign that the marrow is rebuilding rather than a cause for alarm.

Beyond growth factors, corticosteroids at high doses can cause a mild left shift by mobilizing cells from the marrow. Lithium, used in psychiatry, is known to stimulate granulocyte production and can occasionally result in circulating immature forms. In all these medication-related scenarios, the myelocytes tend to disappear once the drug is discontinued or the marrow finishes recovering.

Pregnancy and Other Physiological Causes

Not every appearance of myelocytes in the blood signals disease. Pregnancy is one of the better-documented physiological conditions in which immature granulocytes rise without any underlying pathology. A study of healthy pregnant women found that immature granulocyte counts increase significantly as pregnancy progresses, particularly during the second and third trimesters, and the researchers established trimester-specific reference ranges to help clinicians avoid misinterpreting normal pregnancy changes as signs of infection or disease.⁹

The likely explanation is that pregnancy places the immune system under sustained physiological stress. The body needs to maintain a delicate balance between tolerating the fetus (which is genetically half foreign) and staying ready to fight infections. Increased marrow activity during pregnancy, combined with the expanded blood volume, leads to small numbers of immature cells spilling into circulation. Severe physical stress from other causes, including major trauma, extensive burns, and extreme exercise, can produce similar transient elevations. In these situations, the myelocytes generally resolve on their own once the stressor passes.

Severe hemolytic anemia, where red blood cells are destroyed faster than the marrow can replace them, represents another non-malignant cause. When red cell destruction is extreme, the marrow goes into overdrive to compensate, and this frantic activity can spill immature white cells into the blood alongside the immature red cells the body urgently needs. In rare cases, the body even begins producing blood cells outside the marrow entirely, in the spleen, liver, or other organs, a process called extramedullary hematopoiesis.¹⁰

How Myelocytes Are Counted

Myelocytes and other immature granulocytes can be identified in two ways: by a human technician looking through a microscope at a stained blood smear, or by an automated blood cell analyzer. The traditional manual approach involves a technician examining a few hundred cells on a glass slide, identifying each by its appearance, and calculating the percentage of immature forms. This method is accurate in skilled hands but slow, and results can vary considerably between different technicians.

Modern automated analyzers have largely taken over the initial screening. Machines like the Sysmex series use a combination of light scattering and fluorescent staining to measure cell granularity and nucleic acid content, distinguishing immature granulocytes (promyelocytes, myelocytes, and metamyelocytes as a group) from mature neutrophils. Automated counters offer better precision and consistency than manual counts, with one evaluation finding a correlation coefficient of 0.83 between the automated and manual immature granulocyte counts.¹¹ The automated approach also removes much of the observer-to-observer variability that plagues manual differential counts.¹²

One practical point: most automated analyzers report immature granulocytes as a combined group (the “IG” parameter) rather than breaking them down into individual stages. If your lab report shows an elevated IG count or IG percentage, it could include myelocytes, metamyelocytes, and promyelocytes lumped together. When a more detailed breakdown matters, a pathologist or lab technician will review a manual blood smear to determine exactly which immature forms are present and in what proportions. This distinction sometimes matters for diagnosis, since the specific stage of the immature cells can offer clues about the underlying cause.

What High Myelocytes Suggest About Prognosis

Beyond their diagnostic value, circulating immature granulocytes carry prognostic information, particularly in critically ill patients. In patients with sepsis, a higher percentage of immature granulocytes at admission independently predicted worse outcomes. After adjusting for other risk factors, an elevated immature granulocyte percentage was associated with about a 35% increase in the risk of death at 30 days, and this association persisted at 60 and 90 days as well.¹³

This makes intuitive sense. A higher burden of immature cells in the blood generally reflects a more severe physiological insult, whether that is a worse infection, more advanced cancer, or more extensive marrow damage. The marrow does not release myelocytes casually; it does so when demand is high enough that the normal quality-control process gets bypassed. The more immature cells you see, the harder the system is being pushed.

That said, immature granulocyte counts alone do not reliably distinguish between the various causes. In the study of systemic inflammation mentioned earlier, myelocyte and metamyelocyte levels were higher in patients with confirmed sepsis than in healthy people, but they did not clearly separate patients with definite sepsis from those with suspected sepsis or other inflammatory conditions.² In other words, myelocytes tell you something is wrong and give you a rough sense of severity, but they cannot by themselves tell you what is wrong.

What to Make of Myelocytes on Your Lab Report

If you see myelocytes flagged on a complete blood count, the clinical significance depends entirely on the context. A small number of immature granulocytes during the third trimester of pregnancy or three days after a round of chemotherapy with growth factor support is expected and generally harmless. Myelocytes appearing alongside a high white cell count and fever in someone who feels acutely ill point toward a serious infection. Myelocytes that show up on a routine blood test in someone who feels fine and has no obvious explanation are the scenario that warrants the most careful follow-up, because this pattern can be an early sign of a bone marrow disorder.

Doctors typically approach the finding in layers. The first step is repeating the blood count and reviewing the full differential to see which immature forms are present and in what quantities. If the clinical picture suggests infection, blood cultures and imaging may follow. If infection seems unlikely, or if the immature cells persist after an infection resolves, further workup usually includes a peripheral blood smear review by a hematopathologist and potentially a bone marrow biopsy to look for leukemia, myelofibrosis, or metastatic cancer.

One common source of confusion is the difference between a mild left shift showing a few extra band cells and a true myelocyte elevation. Band cells are one step more mature than metamyelocytes and two steps more mature than myelocytes. A modest increase in bands during a routine infection is extremely common and rarely worries anyone. Myelocytes showing up in meaningful numbers represents a deeper shift, suggesting either a more intense demand or a more fundamental disruption in marrow function. The distinction between “a few extra young neutrophils” and “the marrow is releasing cells that are nowhere near ready” is clinically significant, even though both get loosely described as a left shift.

Distinguishing Reactive Causes from Malignant Ones

One of the trickiest clinical challenges when myelocytes appear is figuring out whether the cause is reactive (the marrow responding appropriately to an outside stressor) or malignant (the marrow itself is diseased). Several features help clinicians make this distinction. In reactive causes like infection, the immature cells typically appear alongside signs of infection such as fever, elevated inflammatory markers, and a source of infection that can be identified. The white cell count may be very high, but the cells usually show a normal maturation sequence: you see progressively fewer cells at each immature stage, with most being bands and mature neutrophils and only a small proportion being myelocytes.

In malignant conditions like CML, the pattern tends to look different. The blood shows a wider spread of maturation stages, sometimes with a “bulge” at intermediate stages. There may be an increase in basophils or eosinophils alongside the myelocytes. Platelet counts and red cell counts may be abnormal in directions that do not fit an infection picture. And critically, the immature cells persist or increase over time rather than resolving as an infection clears.

When myelocytes appear with nucleated red blood cells, the leukoerythroblastic pattern described earlier, the differential shifts toward marrow infiltration or fibrosis rather than simple reactive change. In these cases, the marrow’s physical structure is being disrupted, allowing both red and white cell precursors to escape into the blood. This pattern deserves prompt investigation regardless of whether the patient feels sick, because it can indicate metastatic cancer that has not yet caused symptoms through other routes.

Ultimately, a finding of myelocytes on a blood count is best understood as a marker of marrow stress rather than a diagnosis in itself. The cells are messengers. They tell you the bone marrow is working harder or differently than it should be, and the clinical job is to figure out why. In most acute settings, infection turns out to be the answer. But when infection is excluded, the list of remaining possibilities is important enough that the finding should not be dismissed.